COMPANY INFO
NewLimit is a biotechnology research company founded in 2022 by Blake Byers, Brian Armstrong, and Jacob Kimmel. The company, headquartered in South San Francisco, California, has about 37 to 43 employees and focuses on developing epigenetic reprogramming therapies to extend human healthspan. Their website is https://www.newlimit.com.
NewLimit is a biotechnology research company focused on developing epigenetic reprogramming therapies to extend human healthspan. Founded in 2022, NewLimit’s mission is to harness advanced genomics and artificial intelligence to revolutionize aging and cellular rejuvenation.
The NewLimit leadership team blends accomplished biotech innovators, prolific software entrepreneurs, and internationally recognized scientists. Their backgrounds span world-leading academic research, venture investing, large-scale technology scaling, and therapeutic R&D. Together, the NewLimit management team is shaping the company’s direction, spearheading both operational efficiency and scientific breakthroughs, and positioning NewLimit at the forefront of longevity and healthspan innovation.
As a Co-founder of NewLimit, Blake Byers shapes the company’s strategic vision, guides major investment decisions, and leverages his deep connections in both tech and biotech ecosystems to accelerate the development of epigenetic reprogramming therapies. His leadership has been instrumental in securing funding, forging partnerships, and positioning NewLimit as a leading innovator in healthspan extension.
Blake holds a PhD and MS in Bioengineering from Stanford University, and dual BS degrees in Biomedical Engineering and Economics from Duke University. He spent a decade as a General Partner at GV where he led investments in tech and healthcare firms, including notable biotech successes such as Forty Seven, Arcus, Denali, and Grail. He has incubated companies like Pact Pharma and invested in ventures including Neuralink, Vial, Benchling, and Freenome.
As Co-founder of NewLimit, Brian Armstrong brings his expertise in scaling technology platforms and organizational design to drive the company’s growth and operational excellence. He focuses on integrating software, machine learning, and fundraising strategies to support NewLimit’s mission of developing epigenetic therapies for human healthspan extension.
Brian is the co-founder and long-time CEO of Coinbase, where he grew the company from inception to a publicly traded leader in cryptocurrency with thousands of employees and billions in revenue. He holds a Master’s degree in Computer Science and a Bachelor’s degree in Economics from Rice University, and has deep experience in software engineering, machine learning, leadership, and fundraising.
As Co-founder & President, Jacob Kimmel leads strategic research initiatives and oversees the scientific direction of NewLimit. He drives the application of genomics and machine learning to uncover cellular reprogramming strategies, aligning research programs with the company’s mission to rejuvenate aged cells and extend healthspan.
Jacob holds a PhD in Stem Cell Biology from the University of California, San Francisco. Before NewLimit, he was a Principal Investigator and Computational Fellow at Calico, where he led a lab focused on epigenetic reprogramming, developing computational tools and experimental methods to identify and manipulate cell identity programs.
As Head of Operations, Cathy O'Hare designs and oversees NewLimit’s operational infrastructure, ensuring that research, development, and corporate functions run efficiently. She fosters a collaborative company culture, builds high-performance teams, and implements processes to manage complex scientific projects with precision and agility.
Cathy earned her PhD in Neuroscience from the University of California, San Francisco, followed by postdoctoral fellowships at the University of Cambridge and UC Berkeley. She served as VP and Global Development Lead at GSK and led US Operations and Pharma partnering at a diagnostics company. Her expertise spans medicines development, diagnostics, and digital health solutions.
As a Scientific Advisor, Alex Marson provides expert guidance on gene editing and immunology to inform NewLimit’s therapeutic strategies. His insights help shape research approaches and accelerate innovation in epigenetic reprogramming for immune and cellular rejuvenation.
Alex is a Professor at UCSF, Scientific Director of Human Health at the Innovative Genomics Institute, and Head of the Gladstone-UCSF Institute of Genomic Immunology. He holds an AB and MD from Harvard and a PhD from MIT, and trained in internal medicine at Brigham and Women’s Hospital and in infectious diseases at UCSF.
As a Scientific Advisor, E. John Wherry advises on immunological profiling and epigenetic regulation of T cell states, informing NewLimit’s design of therapies targeting immune aging. His expertise guides the company in translating fundamental immunology discoveries into therapeutic interventions.
Dr. Wherry is the Barbara Schiffrin President’s Distinguished Professor at the University of Pennsylvania’s Perelman School of Medicine, where he chairs the Department of Systems Pharmacology and Translational Therapeutics. He earned his PhD in Immunology at Thomas Jefferson University and a BS from Pennsylvania State University, pioneering research on T cell exhaustion and checkpoint blockade.
As a Scientific Advisor, Hao Zhu contributes knowledge of organ regeneration and somatic mosaicism to inform NewLimit’s development of reprogramming therapies for tissue repair and healthspan extension. His clinical and research insights help bridge basic science with therapeutic applications.
Hao is a Professor at UT Southwestern and holds the Hamon Distinguished Chair in Therapeutic Oncology Research. He earned a BS from Duke University and an MD from Harvard Medical School/MIT, completed clinical training at UCSF and Dana-Farber, and postdoctoral research at Boston Children’s Hospital. His lab focuses on liver injury, regeneration, and cancer genetics.
As a Scientific Advisor, Mark M. Davis guides NewLimit on systems-level immune monitoring and T cell receptor biology to support development of epigenetic interventions for immune rejuvenation. His expertise informs assay design and translational research strategies.
Dr. Davis is the Director of the Stanford Institute for Immunology, Transplantation and Infection and a Howard Hughes Medical Institute Investigator. He holds a BA from Johns Hopkins University and a PhD from Caltech, and is renowned for identifying T cell receptor genes and pioneering systems immunology approaches.
As a Scientific Advisor, Markus Grompe advises on gene and cell therapy strategies, particularly for metabolic and liver disorders, guiding NewLimit’s exploration of organ-level reprogramming therapies. His experience helps strategize translational pathways for epigenetic treatments.
Dr. Grompe is a Professor at Oregon Health & Science University and Director of the Oregon Stem Cell Center. He holds an MD from the University of Ulm, trained at OHSU and Baylor College, and co-founded Ambys Medicines and Yecuris. His lab developed foundational models for hepatocyte repopulation and humanized liver systems.
The NewLimit leadership structure features a blend of scientific founders and operational experts supported by distinguished scientific advisors. This diverse management team brings deep expertise from academic research, clinical development, tech entrepreneurship, and global pharma, enabling NewLimit to execute on its ambitious mission in biotechnology and healthspan extension. With its founders at the helm and a world-class advisory panel, NewLimit is well-positioned to lead advances in epigenetic therapies and aging research.
Websets is a powerful natural language search and data enrichment tool that helps you research executive teams for any company. Whether you're analyzing the NewLimit leadership team or exploring management structures at other organizations, Websets provides comprehensive insights into executive backgrounds, roles, and team dynamics.
With Websets, you can access detailed executive team profiles, management structures, and leadership insights through intuitive natural language queries. Sign up now to enhance your executive team research capabilities.